biospace med Release: Clinical Study Demonstrates EOS Reduces Patient’s Radiation Exposure By Up To 89% Compared To Standard CR X-Rays While Substantially Improving Image Quality

CAMBRIDGE, Mass. & PARIS--(BUSINESS WIRE)--biospace med (www.biospacemed.com) announced today that a 50-patient clinical study published in the current issue of the peer-reviewed medical journal Spine demonstrates that the Company’s ultra-low-dose 2D/3D imaging system, EOS, shows “significantly better” image quality compared to a CR (Computed Radiography) x-ray system while “substantially reducing (a) patient’s (radiation) dose exposure” by up to 9 times (89%) compared to CR imaging. EOS is FDA-cleared and CE-marked.